Is TB-500 FDA approved? The direct answer

Last updated 2026-07-25

Is TB-500 FDA approved for any use?

No. There is no FDA-approved drug called TB-500, and there's no approved indication (wound healing, muscle injury, tendon repair, anything) attached to it. You can check this yourself in Drugs@FDA, the agency's own database of approved drug products ^[1]. Search it for TB-500 or thymosin beta-4 and you'll find nothing, because nothing has cleared an FDA approval pathway under those names. That's a different question from whether TB-500 is legal to possess or whether a pharmacy can prepare it. Those turn on separate rules (compounding law, research-use restrictions), which we cover below in the [legality section](#is-tb-500-legal-to-buy-or-possess). But the plain approval question has a plain answer: no.

What exactly is TB-500, and how is it different from thymosin beta-4?

Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein found in nearly every mammalian cell. It has a documented role in actin regulation, cell migration, and wound healing biology, which is why it attracted interest as a therapeutic candidate in the first place. TB-500 is not the same molecule. It's typically sold as a synthetic fragment, and analytical chemistry papers have specifically characterized the compound marketed as TB-500 as the N-terminal acetylated 17-23 fragment of thymosin beta-4, not the full-length protein ^[2]. That distinction matters a lot, because most of the biological data people cite for 'TB-4' technically comes from research on the native, full-length protein, not the short fragment being sold under the TB-500 name. Sloppy sourcing conflates the two constantly. A 2024 paper in the Journal of Chromatography B went as far as running its own wound-healing screens on TB-500 and its metabolites in vitro and in rats, using UHPLC-Q-Exactive Orbitrap MS/MS to actually track what the compound and its breakdown products do ^[3]. That's useful precisely because it treats TB-500 as its own analytical subject rather than assuming it behaves identically to native Tβ4. For more on how this fragment relates to the parent protein and dosing questions, see our TB-500 dosing guide.

What does the actual research say TB-500 does?

The honest answer: mostly preclinical signals, not clinical proof. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons' Global Research & Reviews covers therapeutic peptides in orthopaedics broadly, including the applications and challenges facing peptides like TB-500 as they move (or don't move) toward clinical use ^[4]. A companion piece in the American Journal of Sports Medicine, framed as a primer for orthopaedic and sports medicine physicians on injectable peptide therapy, covers the same terrain from the clinician's side: what these compounds are being used for off-label, and what physicians are actually seeing ^[5]. A 2026 paper in Sports Medicine (Auckland) looked specifically at safety and efficacy across approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, which is the most direct attempt in this research pack to weigh TB-500-type compounds against the evidence bar that would matter for approval ^[6]. None of this is the same as a randomized controlled trial in humans establishing a dose, an indication, and a safety profile the way FDA approval requires. If you're picturing Phase III data, that doesn't exist for TB-500. What exists is mechanistic and animal work, some analytical chemistry, and clinician-facing reviews describing a landscape, not a verdict. If you're weighing TB-500 against its common pairing, our BPC-157 and TB-500 stack overview walks through what that combined evidence base actually looks like.

Why isn't TB-500 FDA approved yet?

Because nobody has taken it through the trials the FDA requires, and it's not clear anyone is positioned to. FDA approval means a sponsor filed a New Drug Application, ran controlled human trials establishing safety and efficacy for a specific indication and dose, and the agency signed off. You can check any product's status yourself at Drugs@FDA ^[1]. TB-500 has none of that paperwork behind it. Part of the problem is economic. Short peptide fragments derived from naturally occurring proteins are hard to patent tightly, which weakens the incentive for a company to fund the tens of millions of dollars a full approval program costs. Part of it is scientific: the review literature describes real challenges facing peptide therapeutics broadly in orthopaedics, more than funding gaps ^[4]. And part of it is that most of the current work is still preclinical, meaning there isn't yet a clean human dataset to file with regulators even if someone wanted to.

Is TB-500 legal to buy or possess?

This is where things get genuinely confusing, and it's worth separating three different things: FDA drug approval, compounding law, and criminal law. FDA approval, as covered above, doesn't exist for TB-500. Compounding law is a separate track. Under 21 U.S.C. 353a, licensed pharmacies can compound certain preparations for individual patients under specific conditions ^[7]. The FDA maintains bulk drug substance lists for 503A pharmacies (21 CFR 216.23) and 503B outsourcing facilities (21 CFR 216.24) that define which raw ingredients are permitted for compounding ^[8][9]. The agency's own bulk drug substances page for 503A compounding explains the nomination and evaluation process ^[10], and its current nominated substances list is public ^[11]. TB-500 is not on the 503A Bulks List. That's a real regulatory gap: it means compounding TB-500 (or thymosin beta-4) for patient-specific use sits outside the clearly-approved lane, even though it isn't a scheduled controlled substance either. This is exactly why any legitimate access route runs through a provider evaluation and a licensed pharmacy relationship, not a straight retail purchase, and why marketing language matters under 21 CFR 201.128, which defines how a product's intended use is established by labeling, advertising, and context ^[12].

Can you actually buy 'TB-500' as its own product?

Not in any form that should reassure you. There is no standalone TB-500 SKU dispensed through a legitimate pharmacy pathway. What you'll find instead, where a provider-reviewed process exists, is a BPC-157/TB-500 blend, prepared to order rather than sold off a shelf. That distinction is not cosmetic. If you see 'pure TB-500,' 'TB-500 only,' or a product claiming isolated single-peptide status sold directly to consumers with no provider step at all, treat that as a red flag, not a selling point. TB500Co works from the position that access should go through provider review and a named pharmacy partner, which is a very different model than a website selling loose vials with a syringe. Our guide to how the BPC-157/TB-500 blend is typically sourced covers what a legitimate provider-reviewed process actually looks like step by step.

Is TB-500 banned in sports? What does WADA say?

Yes, it's prohibited. TB-500 and thymosin beta-4 fall under the World Anti-Doping Agency's prohibited list categories covering growth factors and related compounds, and this isn't a theoretical concern; there's a real analytical chemistry literature built specifically to catch it. A 2012 paper in the Journal of Chromatography A developed a doping control method for TB-500 detection in equine urine and plasma ^[13], and a related 2013 paper in Analytical and Bioanalytical Chemistry covered detection of seven bioactive peptides, TB-500 among them, in horse plasma ^[14]. This is horse racing testing infrastructure, which tells you something: labs built dedicated LC-MS methods because TB-500 is being used in performance contexts specifically enough to justify it. The human doping side has its own literature. A 2014 review in Expert Review of Proteomics covers detection strategies for peptidic drugs and analogs in sports doping generally ^[15], and a separate 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis covers analytical approaches for emerging therapeutics and non-approved drugs in human doping controls ^[16]. Researchers have also studied practical detection problems specific to TB-500, like adsorption effects that make the peptide stick to lab surfaces and complicate testing accuracy ^[17]. If you compete under WADA or a WADA-aligned body, TB-500 use carries real sanction risk, full stop.

How is TB-500 detected in doping tests, and does that tell us anything useful?

Yes, and it's actually informative beyond sports. Because TB-500 is a small peptide (well under 2 kDa), it needs different detection chemistry than larger protein drugs. A 2016 paper in the Journal of Separation Science covers simplifying screening for peptides under 2 kDa using direct urine injection combined with liquid chromatography and ion mobility mass spectrometry ^[18]. Sample prep matters too: a 2016 Drug Testing and Analysis paper covers solid-phase extraction methods for small bioactive peptides from human urine using cartridges and microelution plates ^[19]. On the metabolism side, a 2015 paper in the Journal of Peptide Science reviews in vitro models used to study how small peptide hormones like TB-500 break down in the body, which matters for figuring out detection windows ^[20]. A 2016 Journal of Proteomics paper compared several in vitro model systems (proteolytic enzymes, human blood serum, liver and kidney microsomes, liver S9 fraction) specifically for metabolizing synthetic doping peptides ^[21]. Put together, this body of work tells you TB-500 does get metabolized and cleared, it doesn't sit around unchanged, and labs have built real infrastructure to catch it anyway. That's a different kind of evidence than a clinical trial, but it's not nothing: it confirms the compound behaves like a real, absorbable, metabolizable peptide in biological systems, which is part of why the preclinical wound-healing work is worth taking seriously even without human trial data.

Is TB-500 the same thing as a growth hormone or steroid, legally speaking?

No, and this confusion trips people up. TB-500 is a peptide fragment, not an anabolic steroid and not a growth hormone or growth hormone releasing compound in the classic sense. It doesn't fall under anabolic steroid control statutes the way testosterone analogs do. Its regulatory gap is different: it's simply an unapproved drug substance with no FDA-cleared indication and no spot on the approved 503A bulk compounding list ^[8]. That said, 'not a controlled substance' doesn't mean 'cleared for consumer sale.' The FDA's intended-use framework under 21 CFR 201.128 means a seller's claims (what they say the product does, how they market it) can independently create legal exposure even for a substance that isn't scheduled ^[12]. This is part of why credible sourcing routes lean on provider evaluation rather than direct-to-consumer marketing claims.

What about safety data, since it isn't FDA approved?

Thin, honestly, at the human level. Because there's no FDA approval process behind TB-500, there's no formal Phase I-III safety dataset the way there would be for an approved drug. What exists is preclinical work (the rat wound-healing study is a good example ^[3]) and review-level commentary from clinicians describing what they observe in off-label use, as in the American Journal of Sports Medicine primer ^[5] and the Sports Medicine safety and efficacy review ^[6]. A 2026 paper in Frontiers in Aging on therapeutic peptides in gerontology covers mechanisms and applications relevant to healthy aging broadly, which is worth knowing about if you're seeing TB-500 discussed in longevity contexts, but again, that's mechanism-and-application review territory, not a controlled trial proving safety in humans at a given dose ^[22]. If you want to understand how TB-500 use and BPC-157 pairing questions play out for a specific population, see our coverage of TB-500 in women, which addresses sex-specific safety questions the general literature doesn't isolate.

If it's not FDA approved, why do clinics offer it?

Because 'not FDA approved' and 'not legally accessible in any form' aren't the same thing, and clinics are working the compounding and off-label space, not claiming FDA approval. Some physicians write for compounded preparations under state-licensed pharmacy relationships, using the same general legal mechanism (21 U.S.C. 353a) that lets pharmacies compound plenty of non-FDA-approved-but-legitimately-prescribed preparations ^[7]. The catch, again, is that TB-500 sits outside the FDA's confirmed 503A bulk substance list, so this access route depends heavily on which pharmacy you're working with and how they're interpreting that gap. This is exactly the reason a provider-reviewed process matters more here than with an approved drug. There's no FDA monograph to fall back on for dosing or contraindications. A prescriber who's actually reviewed your history and a pharmacy that's compounding to a documented process is a meaningfully different risk profile than an anonymous online seller.

What should you actually do with this information?

Don't buy into 'FDA approved' claims for TB-500 anywhere, because they're false on their face; you can verify that yourself at Drugs@FDA in under a minute ^[1]. Do treat the preclinical wound-healing and orthopaedic review literature as a real, if early, signal, not proof ^[3][4][5][6]. Do assume WADA prohibition applies if you compete ^[13][14]. If you're going to pursue this at all, the sane path is provider evaluation followed by a licensed pharmacy compounding the preparation, typically as a BPC-157/TB-500 blend rather than an isolated TB-500 product, since no standalone TB-500 SKU exists through legitimate channels. TB500Co's own position is to route readers toward that provider-reviewed, named-pharmacy path rather than direct retail purchase, precisely because the regulatory gap described above (no FDA approval, no 503A bulk listing) means the sourcing decision carries more weight than it would for an approved medication.

Frequently asked questions

Is TB-500 FDA approved for wound healing or injury recovery?

No. There is no FDA-approved drug product called TB-500 for any indication, including wound healing or injury recovery. Check Drugs@FDA directly; it returns nothing under that name because no sponsor has completed an approval pathway for it.

Is TB-500 the same as thymosin beta-4?

Not exactly. Thymosin beta-4 is the full 43-amino-acid native protein. TB-500 is generally characterized as the N-terminal acetylated 17-23 fragment of that protein, a distinct, shorter synthetic compound, per analytical chemistry work published in Drug Testing and Analysis in 2012.

Can a pharmacy legally compound TB-500?

Compounding law (21 U.S.C. 353a) allows licensed pharmacies to prepare certain non-approved substances for individual patients, but TB-500 is not on the FDA's confirmed 503A bulk drug substance list, which creates a real gray area depending on how a given pharmacy interprets and documents its compounding decision.

Is TB-500 banned by WADA?

Yes. TB-500 and thymosin beta-4 fall under WADA's prohibited categories for growth factors and related peptides. Dedicated LC-MS detection methods exist specifically for TB-500 in equine and, by extension, doping-relevant human testing contexts, confirming it's an active testing target, not an overlooked loophole.

Does TB-500 have human clinical trial data?

No controlled human trial data of the kind FDA approval requires exists in the current literature reviewed here. What's available is preclinical (cell and animal) research plus clinician-facing review articles describing off-label use patterns, not Phase I-III safety and efficacy trials.

Can you buy TB-500 as a standalone product legally?

Not through a legitimate, provider-reviewed pathway. There's no standalone TB-500 SKU dispensed by licensed pharmacies; where it's available at all, it's compounded as a BPC-157/TB-500 blend after a provider evaluation, not sold as an isolated retail product.

Why isn't there more research on TB-500 specifically, versus thymosin beta-4?

Much of the older 'TB-4' literature studied the native full-length protein, not the short TB-500 fragment sold today. Newer work, like a 2024 Journal of Chromatography B study using UHPLC-Q-Exactive Orbitrap MS/MS, has started studying TB-500 and its metabolites directly, but this body of work is still small and mostly preclinical.

Is TB-500 detectable in a drug test?

Yes. Because it's a small peptide under 2 kDa, specialized methods like direct urine injection with ion mobility mass spectrometry and solid-phase extraction protocols have been developed specifically to detect it, as covered in Journal of Separation Science (2016) and Drug Testing and Analysis (2016) papers.

Is TB-500 a steroid or a growth hormone?

No. It's a peptide fragment, structurally and legally distinct from anabolic steroids and growth hormone. Its regulatory issue isn't controlled-substance scheduling; it's that it has no FDA approval and isn't on the approved 503A compounding bulk substance list.

What does the 2026 orthopaedic literature actually say about TB-500?

Review articles in JAAOS Global Research & Reviews and The American Journal of Sports Medicine (both 2026) describe TB-500 and similar peptides as part of a growing but still largely preclinical and off-label landscape in orthopaedic and sports medicine, flagging real challenges before wider clinical adoption, not a settled evidence base.

Does BPC-157 change TB-500's FDA status?

No. Pairing TB-500 with BPC-157 in a compounded blend doesn't grant either compound FDA approval. Both remain unapproved substances; the blend format simply reflects how compounding pharmacies typically prepare and dispense this combination for provider-directed use.

Is it safe to use TB-500 if it isn't FDA approved?

Nobody has a clean human safety dataset to point to, since no FDA approval process has generated one. Safety signals come from preclinical animal studies and clinician review commentary, which is a meaningfully lower evidence bar than what governs an approved drug's labeling.

Sources

1. FDA, Drugs@FDA database: TB-500 has no FDA-approved drug application or indication listed in the agency's approved drug products database
2. Drug Testing and Analysis, 2012 (PMID 22962027): TB-500 is characterized as the N-terminal acetylated 17-23 fragment of thymosin beta-4, distinct from the full-length native protein
3. Journal of Chromatography B, 2024 (PMID 38382158): Quantified TB-500 and its metabolites in vitro and in rats using UHPLC-Q-Exactive Orbitrap MS/MS and screened wound-healing activity
4. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Reviews applications, challenges, and future directions for therapeutic peptides in orthopaedics, including compounds like TB-500
5. American Journal of Sports Medicine, 2026 (PMID 41476424): Provides a primer for orthopaedic and sports medicine physicians on injectable peptide therapy use patterns
6. Sports Medicine (Auckland), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance
7. 21 U.S.C. 353a, pharmacy compounding: Establishes the legal mechanism allowing licensed pharmacies to compound preparations for individual patients under specific conditions
8. 21 CFR 216.23, the 503A Bulks List: Defines the approved bulk drug substances list for 503A pharmacy compounding, which does not include TB-500
9. 21 CFR 216.24, the 503B Bulks List: Defines the approved bulk drug substances list for 503B outsourcing facility compounding
10. FDA, bulk drug substances used in compounding under section 503A: Explains the FDA's process for nominating and evaluating bulk drug substances for 503A compounding use
11. FDA, bulk drug substances nominated for use in compounding (current list): Public list of substances nominated for 503A compounding evaluation, used to confirm TB-500's listing status
12. 21 CFR 201.128, meaning of intended uses: Defines how a product's labeling and marketing claims establish its legal intended use, independent of scheduling status
13. Journal of Chromatography A, 2012 (PMID 23084823): Developed an LC-MS doping control method to detect TB-500 in equine urine and plasma
14. Analytical and Bioanalytical Chemistry, 2013 (PMID 23318763): Developed doping control analysis for seven bioactive peptides including TB-500 in horse plasma
15. Expert Review of Proteomics, 2014 (PMID 25382550): Reviews current detection strategies and future directions for peptidic drugs and analogs in sports doping
16. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Covers analytical approaches for detecting emerging therapeutics and non-approved drugs in human doping controls
17. Analytical Biochemistry, 2017 (PMID 28887173): Documents adsorption effects that complicate laboratory detection accuracy for TB-500 among other doping-relevant peptides
18. Journal of Separation Science, 2016 (PMID 26578461): Developed a simplified screening method for peptides under 2 kDa using direct urine injection and ion mobility mass spectrometry
19. Drug Testing and Analysis, 2016 (PMID 26472487): Developed solid-phase extraction methods for small bioactive peptides from human urine samples
20. Journal of Peptide Science, 2015 (PMID 25469748): Reviews in vitro models used to study metabolism of small peptide hormones in sport drug testing
21. Journal of Proteomics, 2016 (PMID 27569051): Compares in vitro model systems for metabolizing synthetic doping peptides, relevant to TB-500 detection windows
22. Frontiers in Aging, 2026 (PMID 42021992): Reviews mechanisms and applications of therapeutic peptides in gerontology and healthy aging contexts